Goldline Pharmaceutical Shares Debut 40% Higher On BSE SME

Goldline Pharmaceutical shares made a strong market debut on the Bombay Stock Exchange (BSE) SME platform on Monday, listing at ₹59.75 against the initial public offering (IPO) issue price of ₹43 per share. The listing marked a gain of nearly 40% for investors. The stock extended gains after listing and touched an intraday high of ₹60 apiece.

Soon after, profit booking emerged, and the stock hit the 5% lower circuit limit at ₹56.77 per share. The listing comes days after the company closed its ₹11.61 crore initial public offering. At 11:54 am, Goldline Pharmaceutical shares were trading at ₹56.8 on the BSE SME.

IPO Was Entirely Fresh Issue

The Goldline Pharmaceutical IPO was through the book-building route. The issue consisted entirely of a fresh issue of 27 lakh equity shares. The company had fixed the IPO price band at ₹41 to ₹43 per equity share with a face value of ₹10 each.

Investors were required to bid for a minimum lot size of 3,000 equity shares. Additional bids could be placed in multiples of 3,000 shares thereafter. The IPO opened for subscription on 12 May and closed on 14 May. Cumulative Capital Pvt. Ltd. acted as the book-running lead manager to the issue.

Bigshare Services Pvt. Ltd was appointed as the registrar for the IPO, while Nirman Share Brokers Pvt. Ltd served as the market maker.

Funds To Be Used For Debt Repayment

According to the company, a major portion of the IPO proceeds will go towards reducing debt. Goldline Pharmaceutical plans to use around ₹8.35 crore from the issue proceeds for repayment of loans. The remaining amount will be used for general corporate purposes. As of March 2026, the company’s total outstanding debt stood at ₹9.13 crore.

Also Read - Arohan Financial Services Files DRHP For ₹600 Crore IPO

Company Operates Across Multiple Therapy Segments

Goldline Pharmaceutical markets pharmaceutical products under its ‘Goldline’ brand and operates through five business divisions:

• Goldline Pharma

• Goldline Cardinal

• Goldline Aayushman

• Goldline InLife

• Goldline Wellness

The company’s product portfolio covers several therapy areas, including orthopaedics, gastroenterology, neurology, cardiology, endocrinology, paediatrics, neonatal care, critical care and supportive oncology treatment. The listing adds to a series of SME IPOs that have seen strong opening gains in recent months, despite volatile broader market conditions.

Source:

Livemint